PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities
PainReform Ltd. - Ordinary Shares (PRFX)
Company Research
Source: GlobeNewswire
TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio’s proprietary drop-less, sustained-release ocular drug-delivery platform. The assessment confirmed that its sustained release, polymer matrix platform can incorporate a variety of drug entities, reinforcing its long-term potential to provide greatly improved pharmacological efficiency and simplify postoperative care for cataract patients by reducing or eliminating the need for medicated eye drops – the DROP-LESS advantage. The matrix platform successfully incorporated corticosteroids and NSAIDs—two major therapeutic drug classes routinely used after cataract surgery. The results support the technical feasibility of multi-drug potential. LayerBio’s pre-fabricated OcuRing is placed during cataract surgery via an intraocular route, enabling sustained-release drug delivery to targeted ocular tissues. By providin
Show less
Read more
Impact Snapshot
Event Time:
PRFX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRFX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRFX alerts
High impacting PainReform Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRFX
News
- PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular TherapyGlobeNewswire
- PainReform’s DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset AnalysisGlobeNewswire
- PainReform’s DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot ProjectsGlobeNewswire
- PainReform (NASDAQ:PRFX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PRFX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- PainReform Provides Business Update for the Six Months Ended June 30, 2025 [Yahoo! Finance]Yahoo! Finance
PRFX
Sec Filings
- 12/10/25 - Form 6-K
- 12/2/25 - Form 6-K
- 11/25/25 - Form 6-K
- PRFX's page on the SEC website